Lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
== Physical and chemical properties == In its isolated or synthesized form, the active compound appears as an amorphous white solid, and elemental analysis shows that it consists of 70.56% carbon, 8.07% hydrogen, and 21.36% oxygen. The distinctive chemical feature of Guanacastepene A stems from the so-called guanacastane skeleton.
=== Influence of timing === As most nutrient supplements feed all living microorganism in the must (whether desirable or not), winemakers will often wait to add the nutrients until they are ready to inoculate the must with their desired S. cerevisiae strain. Producers who are using wild ferments may also wait until after sulfur dioxide additions have killed off unwanted microbes or feed early because they would like the potential complexity that other microbes could add to the wine. When added, the nitrogen is usually in the form of amino acids, combined with vitamins and minerals to help kick start the fermentation.
Note that the incompressible case correspond to the assumption that the pressure constrains the flow so that the volume of fluid elements is constant: isochoric flow resulting in a solenoidal velocity field with
During cancer T cell exhaustion plays a role in tumor protection. According to research some cancer-associated cells as well as tumor cells themselves can actively induce T cell exhaustion at the site of tumor. T cell exhaustion can also play a role in cancer relapses as was shown on leukemia. Some studies have suggested that it is possible to predict relapse of leukemia based on expression of inhibitory receptors PD-1 and TIM-3 by T cells. Many experiments and clinical trials have focused on immune checkpoint blockers in cancer therapy, with some of these approved as valid therapies that are now in clinical use. Inhibitory receptors targeted by those medical procedures are vital in T cell exhaustion and blocking them can reverse these changes.
Sources: en.wikipedia.org
1 of the 20 Greatest WWE Wrestlers Of All Time Texas Wrestling Alliance TWA Tag Team Championship (1 time) – with Rod Price World Championship Wrestling WCW World Television Championship (2 times) WCW United States Heavyweight Championship (2 times) WCW World Tag Team Championship (1 time) – with Brian Pillman NWA World Tag Team Championship (1 time) – with Brian Pillman World Wrestling Federation/World Wrestling Entertainment/WWE WWF Championship (6 times) WWF Intercontinental Championship (2 times) WWF Tag Team Championship (4 times) – with Shawn Michaels (1), Dude Love (1), The Undertaker (1), and Triple H (1) Million Dollar Championship (1 time) King of the Ring (1996) Royal Rumble (1997, 1998, 2001) Undisputed WWF Championship #1 Contenders Tournament (2002) Fifth Triple Crown Champion Slammy Award (2 times) Freedom of Speech (1997) Best Original WWE Network Show – Stone Cold Podcast (2015) WWE Hall of Fame (2 times) Class of 2009 – individually Class of 2025 – Immortal Moment vs. Bret Hart at WrestleMania 13 Wrestling Observer Newsletter Best Box Office Draw (1998, 1999) Best Brawler (2001) Best Gimmick (1997, 1998) Best Heel (1996) Best on Interviews (1996–1998, 2001) Best Non-Wrestler (2003) Feud of the Year (1997) vs. The Hart Foundation Feud of the Year (1998, 1999) vs. Vince McMahon Match of the Year (1997) vs. Bret Hart in a submission match at WrestleMania 13 Most Charismatic (1997, 1998) Rookie of the Year (1990) Tag Team of the Year (1993) with Brian Pillman as The Hollywood Blonds Worst Worked Match of the Year (1991) with Terrance Taylor vs.
Micrococcus, from Ancient Greek μικρός (mikrós), meaning "small", and κόκκος (kókkos), meaning "sphere", is a genus of bacteria in the Micrococcaceae family. Micrococcus occurs in a wide range of environments, including water, dust, and soil. Micrococci have Gram-positive spherical cells ranging from about 0.5 to 3 micrometers in diameter and typically appear in tetrads. They are catalase positive, oxidase positive, indole negative and citrate negative. Micrococcus has a substantial cell wall, which may comprise as much as 50% of the cell mass. The genome of Micrococcus is rich in guanine and cytosine (GC), typically exhibiting 65 to 75% GC-content. Micrococci often carry plasmids (ranging from 1 to 100 MDa in size) that provide the organism with useful traits. Some species of Micrococcus, such as M. luteus (yellow) and M. roseus (red) produce yellow or pink colonies when grown on mannitol salt agar. Isolates of M. luteus have been found to overproduce riboflavin when grown on toxic organic pollutants like pyridine.
=== EC 2.7.2: Phosphotransferases with a carboxy group as acceptor === EC 2.7.2.1: acetate kinase EC 2.7.2.2: carbamate kinase EC 2.7.2.3: phosphoglycerate kinase EC 2.7.2.4: aspartate kinase EC 2.7.2.5: Now EC 6.3.4.16, carbamoyl-phosphate synthase (ammonia) EC 2.7.2.6: formate kinase EC 2.7.2.7: butyrate kinase EC 2.7.2.8: acetylglutamate kinase EC 2.7.2.9: Now EC 6.3.5.5, carbamoyl-phosphate synthase (glutamine-hydrolysing) EC 2.7.2.10: phosphoglycerate kinase (GTP) EC 2.7.2.11: glutamate 5-kinase EC 2.7.2.12: acetate kinase (diphosphate) EC 2.7.2.13: Now known to be due to the activities of EC 6.1.1.17, glutamate—tRNA ligase, EC 1.2.1.70, glutamyl-tRNA reductase and EC 5.4.3.8 glutamate-1-semialdehyde 2,1-aminomutase EC 2.7.2.14: branched-chain-fatty-acid kinase EC 2.7.2.15: propionate kinase EC 2.7.2.16: 2-phosphoglycerate kinase EC 2.7.2.17: [amino-group carrier protein]-L-2-aminoadipate 6-kinase EC 2.7.2.18: fatty acid kinase
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.